secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-02-03T23:59:59+00:00
Accession:  0001193125-23-024123
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics amends bylaws to conform to DGCL and universal proxy rules
-----------------------------------------------------------------------------

- Updated provisions on adjournment, stockholder lists, and electronic transmission of notices to align with recent DGCL amendments.
- Revised advance notice bylaws require additional disclosures, limit nominees to board seats up for election, and mandate nominee interviews.
- Added rules to comply with universal proxy (Rule 14a-19): stockholders must certify compliance and provide evidence 5 business days before meeting.
- Requires stockholders soliciting proxies to use a non-white proxy card; authorizes emergency bylaws for quorum issues.
- Effective February 2, 2023; no financial or operational impact disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523024123/0001193125-23-024123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523024123/d427161d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-024123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer